Definitive Contract 75F40123C00195
Award Date
9/21/23
Potential Completion Date
9/29/24
Potential Value
$523K
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Irving, TX 75063, USA
Solicitation Procedures
Two Step
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a $549,175.31 cost no fee definitive contract to the American College of Emergency Physicians (ACEP) to analyze the usage, safety, and efficacy of naloxone in emergency departments and pre-hospital settings during the COVID-19 pandemic. ACEP is a non-profit professional society for emergency physicians that has received multiple previous federal contracts and grants from the Department of Health and Human Services and Centers for Disease...
This is a definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA) to the American College of Medical Toxicology, Inc. (ACMT), a non-profit organization specializing in medical toxicology. The $1,842,760.00 contract is for a project to characterize the clinical use, risks, benefits, and effectiveness of naloxone in reversing opioid overdoses in pre-hospital settings, using qualitative and quantitative blood toxicology tests. ACMT has previously held contracts and...
This is a delivery order awarded by the Indian Health Service, a civilian agency within the U.S. Department of Health and Human Services, to Emergent Devices, Inc., a for-profit pharmaceutical manufacturer, for a $417,820.68 firm fixed-price contract to provide a stock of NARCAN (naloxone) to the National Supply Service Center (NSSC) warehouse customers. The contract has no set-aside designation and is part of Emergent Devices' existing $11.8 million multiple-award Federal Supply Schedule...
This firm-fixed-price $200,000 purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to the American College of Emergency Physicians (ACEP), a non-profit professional society for emergency physicians. The contract, which has an ultimate completion date of March 31, 2024, involves the provision of data services to the CDC. ACEP has previously received multiple federal contracts and grants from the Department of Health and Human Services to conduct research and provide...
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Health Administration to Emergent Devices, Inc., a for-profit manufacturer of pharmaceuticals and medical devices, to provide naloxone nasal spray. Naloxone is a medication that rapidly reverses opioid overdoses and treats substance abuse. The $946,261.44 firm-fixed-price delivery order was placed against Emergent Devices' Federal Supply Schedule 65 IB contract, which furnishes drugs and hematology...
The Department of Veterans Affairs Veterans Health Administration awarded a $934,410.48 firm fixed-price delivery order to Emergent Devices, Inc. for the provision of naloxone nasal spray. Naloxone is a medication that rapidly reverses opioid overdoses and treats substance abuse. The contract is under the Pharmaceuticals and Drugs Federal Supply Schedule, which allows Veterans Integrated Service Network 12 to procure pharmaceuticals through a streamlined vehicle. Emergent Devices, a for-profit...
This is a delivery order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Emergent Devices, Inc., a for-profit manufacturer, to provide naloxone nasal spray. The contract is a firm-fixed price order under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, with a potential value of $904,465.44. The contract does not have a set-aside designation. Naloxone is a medication that rapidly reverses opioid overdoses and is used to...
The Department of State Bureau of Administration awarded a $141,682.80 firm fixed price delivery order to Emergent Devices, Inc., a for-profit manufacturer, to provide NALOXONE HCI NASAL SPRAY 4MG. This medication rapidly reverses opioid overdoses and treats substance abuse. The contract is not set aside and utilizes the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. Emergent Devices holds a larger Federal Supply Schedule contract to furnish Schedule 65 IB drugs and hematology...
This is a federal contract award to Emergent Devices, Inc., a for-profit pharmaceutical manufacturer, for the delivery of naloxone nasal spray. The contract, valued at $904,465.44, was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12. The contract is a delivery order under Emergent Devices' Federal Supply Schedule 65 IB contract for pharmaceuticals and drugs, which runs through August 2028. Naloxone is a medication used to...
This is a delivery order awarded by the Department of Veterans Affairs Veterans Health Administration (VHA) to Emergent Devices, Inc., a for-profit manufacturer of pharmaceuticals and medical devices. The $904,465.44 contract is for the delivery of NALOXONE HCL 4MG/SPRAY, a medication that rapidly reverses opioid overdose and treats substance abuse. This delivery order was competed on the VHA's Federal Supply Schedule 65 IB contract for pharmaceuticals and drugs, which Emergent Devices holds...